STRO EBITDA | SUTRO BIOPHARMA, INC.

SUTRO BIOPHARMA, INC. (STRO) EBITDA

2026-06-30: Basis Reported; EBITDA -$28.63M*; Operating income -$29.89M; Depreciation and amortization $1.26M*.
2026-03-31: Basis Reported; EBITDA -$28.38M; Operating income (m); Depreciation and amortization (m).
2025-12-31: Basis Reported; EBITDA -$36.43M; Operating income (m); Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA -$46.56M*; Operating income -$48.46M; Depreciation and amortization $1.90M*.

Complete source-backed ebitda history.

Available history: 2016-12-31 to 2026-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	-$28.63M*	-$29.89M	$1.26M*	$9.84M	-290.94%*	(m)	-$38.29M*	(m)	$31.70M	(m)	$1.00K
2026-03-31	Reported	-$28.38M	(m)	(m)	(m)	(m)	(m)	-$42.26M	(m)	$36.55M	(m)	-$15.00K
2025-12-31	Reported	-$36.43M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2025-09-30	Reported	-$46.56M*	-$48.46M	$1.90M*	$9.69M	-480.34%*	(m)	-$38.19M*	(m)	$39.85M	(m)	$0.00
2025-06-30	Reported	-$1.45M*	-$3.35M	$1.90M*	$63.74M	-2.27%*	(m)	-$44.72M*	(m)	$38.33M	(m)	-$18.00K
2025-03-31	Reported	-$66.61M	(m)	(m)	(m)	(m)	(m)	-$67.88M	(m)	$51.60M	(m)	$7.00K
2024-12-31	Reported	-$63.39M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-09-30	Reported	-$66.12M*	-$67.92M	$1.80M*	$8.52M	-776.06%*	(m)	-$64.52M*	(m)	$62.11M	(m)	$0.00
2024-06-30	Reported	-$46.90M*	-$48.69M	$1.79M*	$25.71M	-182.43%*	(m)	$9.46M*	(m)	$62.02M	(m)	$8.00K
2024-03-31	Reported	-$54.83M	(m)	(m)	(m)	(m)	(m)	-$64.74M	(m)	$56.88M	(m)	(m)
2023-12-31	Reported	$44.88M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$42.27M*	-$44.01M	$1.74M*	$16.92M	-249.79%*	(m)	-$33.50M*	(m)	$45.67M	(m)	$1.84M
2023-06-30	Reported	-$44.45M*	-$46.18M	$1.73M*	$10.41M	-426.89%*	(m)	-$31.20M*	(m)	$41.59M	(m)	$151.00K
2023-03-31	Reported	-$40.62M	(m)	(m)	(m)	(m)	(m)	-$60.99M	(m)	$39.40M	(m)	$395.00K
2022-12-31	Reported	-$47.69M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$19.77M*	-$21.21M	$1.44M*	$25.15M	-78.63%*	(m)	$65.85M*	(m)	$31.71M	(m)	$0.00*
2022-06-30	Reported	-$17.98M*	-$19.38M	$1.40M*	$28.10M	-64.00%*	(m)	-$3.19M*	(m)	$32.33M	(m)	$2.50M
2022-03-31	Reported	-$37.81M	(m)	(m)	(m)	(m)	(m)	-$35.26M	(m)	$29.99M	(m)	$0.00
2021-12-31	Reported	-$33.72M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$33.56M*	-$34.67M	$1.12M*	$8.52M	-393.99%*	(m)	-$24.41M*	(m)	$26.60M	(m)	(m)
2021-06-30	Reported	-$8.69M*	-$9.80M	$1.12M*	$28.05M	-30.96%*	(m)	-$5.26M*	(m)	$25.31M	(m)	(m)
2021-03-31	Reported	-$17.72M	(m)	(m)	(m)	(m)	(m)	-$30.43M	(m)	$22.56M	(m)	(m)
2020-12-31	Reported	-$23.67M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$9.65M*	-$10.62M	$967.00K*	$17.82M	-54.14%*	(m)	-$17.69M*	(m)	$19.36M	(m)	(m)
2020-06-30	Reported	-$15.36M*	-$16.42M	$1.06M*	$9.47M	-162.19%*	(m)	-$12.50M*	(m)	$17.24M	(m)	(m)
2020-03-31	Reported	-$18.08M	(m)	(m)	(m)	(m)	$763.00K	-$18.73M	(m)	$17.62M	(m)	(m)
2019-12-31	Reported	-$13.57M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$11.50M*	-$12.73M	$1.23M*	$12.28M	-93.70%*	$667.00K*	-$16.12M*	(m)	$16.90M	(m)	(m)
2019-06-30	Reported	-$12.49M*	-$13.69M	$1.19M*	$10.53M	-118.70%*	$489.00K*	-$15.60M*	(m)	$16.14M	(m)	(m)
2019-03-31	Reported	-$13.13M	(m)	(m)	(m)	(m)	$276.00K	-$20.14M	(m)	$15.18M	(m)	(m)
2018-12-31	Reported	-$2.14M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$9.04M*	-$10.16M	$1.12M*	$7.84M	-115.34%*	$359.00K*	$47.57M*	(m)	$12.64M	(m)	(m)
2018-06-30	Reported	-$10.96M*	-$12.09M	$1.12M*	$5.70M	-192.23%*	$36.00K*	-$13.95M*	(m)	$13.75M	(m)	(m)
2018-03-31	Reported	-$10.54M	(m)	(m)	(m)	(m)	$364.00K	-$15.01M	(m)	$13.08M	(m)	(m)
2017-12-31	Reported	-$13.97M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	(m)	-$1.06M	(m)	(m)	(m)	(m)	(m)	(m)	$13.67M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	-$151.04M	(m)	(m)	(m)	(m)	(m)	-$177.23M	(m)	$166.42M	(m)	-$93.00K
2024-12-31	Reported	-$231.24M	(m)	(m)	(m)	(m)	(m)	-$191.54M	(m)	$252.04M	(m)	$2.36M
2023-12-31	Reported	-$82.46M	(m)	(m)	(m)	(m)	(m)	-$111.62M	(m)	$180.43M	(m)	$18.19M
2022-12-31	Reported	-$123.25M	(m)	(m)	(m)	(m)	(m)	$3.55M	(m)	$137.17M	(m)	$2.50M
2021-12-31	Reported	-$93.68M	(m)	(m)	(m)	(m)	(m)	-$81.68M	(m)	$104.40M	(m)	$0.00
2020-12-31	Reported	-$66.76M	(m)	(m)	(m)	(m)	(m)	-$67.80M	(m)	$76.96M	(m)	$103.00K
2019-12-31	Reported	-$50.69M	(m)	(m)	(m)	(m)	(m)	-$65.02M	(m)	$65.61M	(m)	$0.00
2018-12-31	Reported	-$32.68M	(m)	(m)	(m)	(m)	$1.56M	$12.68M	(m)	$54.26M	(m)	$0.00
2017-12-31	Reported	-$14.28M	(m)	(m)	(m)	(m)	$3.32M	-$37.07M	(m)	$54.64M	(m)	$0.00
2016-12-31	Reported	$7.03M	(m)	(m)	(m)	(m)	$4.39M	-$13.15M	(m)	$43.55M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
Lineage Cell Therapeutics, Inc. (LCTX)	United States	$0.241B	-10.35
FATE THERAPEUTICS INC (FATE)	United States	$0.280B	-2.51
Liminatus Pharma, Inc. (LIMN)	United States	$0.282B
Aligos Therapeutics, Inc. (ALGS)	United States	$0.238B	-0.47
Inhibikase Therapeutics, Inc. (IKT)	United States	$0.296B	-4.44
X4 Pharmaceuticals, Inc (XFOR)	United States	$0.297B	-4.99
Protalix BioTherapeutics, Inc. (PLX)		$0.221B	9.87